Wednesday, February 8, 2023
Market-Reporter
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate
No Result
View All Result
Market-Reporter
No Result
View All Result
Home ETFs

Why you can invest in Nippon India Nifty Pharma ETF NFO

MtR by MtR
June 26, 2021
in ETFs
0


Nippon India has launched a new sector ETF to track Nifty Pharma Index. This index constitutes the ten top Indian pharma companies by market capitalisation (free float). The NFO will close on June 28, 2021 . The fund is targeted at investors who wish to participate in the growth opportunities offered by the Indian pharmaceutical sector in a passive manner, avoiding the risk associated with individual stock selection.

However, sectoral ETFs carry high risk too. The Nifty Pharma index is made up of the largest pharma companies, including Sun Pharmaceuticals, Dr. Reddy’s, Cipla, Lupin and Cadila with largely similar exposure profile: exports (dominated by US), domestic, and third party API sales. Other constituents such as Aurobindo and Biocon are largely export oriented while Alkem and Torrent Pharmaceuticals are domestic focussed.

Divi’s Labs, with exposure to its CRAMS/custom synthesis business, is present as well. CRAMS operations have gained from higher outsourcing in the last five years and the Indian API industry is expected to gain similarly from supply diversification. Post Covid-19, increased healthcare focus by individuals and governments across regions is expected to translate positively for exports and domestic formulations business including vaccine opportunities.

The index rebalances semi-annually based on free float and currently excludes large API focussed operators because of its criterion. Two other index ETFs were launched in May 2021 from ICICI Prudential and Axis, both of which track Nifty Healthcare Index. This index constitutes 20 stocks including three hospitals/diagnostics and remaining 17 from pharmaceuticals. Also, these ETFs have a wider coverage of pharmaceutical stocks including APIs and Indian arms of Pharmaceutical MNCs, compared to the 10 companies tracked by Nippon’s Nifty Pharma ETF. Even as past performance is not indicative, Nifty Healthcare index with 6 per cent CAGR returns in the last five years returned similar to 5 per centCAGR returns from Nifty Pharma index.

Two factors based on historical data, can support a bullish stance on the pharma sector even from this point of elevated stock prices. The Indian pharma industry is coming off a protracted period of industry contraction in the last four years, which inflates the effect of recovery witnessed in the last year. The trailing P/E multiple for the Index as of June 2021, at 36 times, is still some distance from the last decade’s average.

Valuations still reasonable

In the first half of the decade from 2010, the rally in Indian pharma stocks was based on successful launch of limited competition generics in regulated markets utilising loss of patent exclusivities. But the last 3-4 years were marked by client consolidation, increased competition and regulatory challenges in the form of longer approval cycles and adverse plant inspection results. The Index eroded from late 2018 right up to the low point in March 2020. The recovery in the last year was thus on a low base.

The trailing P/E multiple of the index as of June 2021 is trading between lower limit (marked by one standard deviation) and the average of the last decade even as Nifty Pharma index, on an absolute basis, has marginally breached the peak reached earlier in the 2015-16 period. The index, on an absolute basis, appears strong, especially when considered against the last three years’ performance. But on a valuation basis, it seems undervalued and may prove to be a reasonable entry point to long-term investors looking for exposure to passive investing in the Indian pharma space.

Prospects sanguine

From a forward looking view as well, the industry has shrugged off the challenges of the last decade by focussing on moving up the value chain. R&D and other investments of the last four years, necessitated by contraction in US markets, will stand it in good stead in the coming decade. Each of the index constituents focusses on a niche amongst speciality products, biosimilars, vaccines, injectable and complex inhalation products, besides core operations.

Investors can gain from cumulative exposure to these long gestation projects, especially when speculating on company-specific long-term outcomes may seem fraught with risk, either through actively managed funds or individual stock selection. The main risk associated with the sector is that investors have to look out for is companies failing plant inspections by regulators and heightened inspection cycle, post the re-opening of economies.

Index constitutes companies with focus on US exports, domestic markets and third party API sales

Nifty Pharma shows 5% CAGR returns in the last five years

NFO closes on June 28 but will reopen later



Source link

Related articles

Hedge Funds Suffer Outflows as ETFs had Inflows

August 10, 2022

Australia’s 6 biggest ETF providers

August 10, 2022

Related Posts

Hedge Funds Suffer Outflows as ETFs had Inflows

by MtR
August 10, 2022
0

ETFGI, a leading independent research and consultancy firm covering trends in the global ETFs and ETPs ecosystem, reported that the...

Australia’s 6 biggest ETF providers

by MtR
August 10, 2022
0

Exchange Traded Funds or ETFs are now a BIG thing in Australia. The rise of ASX ETFs is making investing...

New Treasury ETFs launch as fixed income ETFs enter “sweet spot”

by MtR
August 9, 2022
0

The U.S. Treasury building is seen in Washington, September 29, 2008. REUTERS/Jim BourgRegister now for FREE unlimited access to Reuters.comRegisterNEW...

SoFi Launches First-of-its-Kind Web 3 ETF and a Smart Energy ETF to Empower People to Invest in the Future | News

by MtR
August 9, 2022
0

SAN FRANCISCO--(BUSINESS WIRE)--Aug 9, 2022--SoFi Technologies, Inc. (“SoFi”), the digital personal finance company, today announced that SoFi Invest1 is launching...

J.P. Morgan Asset Management Launches JPMorgan Active Growth ETF (JGRO)

by MtR
August 9, 2022
0

Unifies two industry-leading growth strategies into one actively managed ETF NEW YORK, Aug. 9, 2022 /PRNewswire/ -- J.P. Morgan Asset Management...

Load More
  • Trending
  • Comments
  • Latest

Bank of England tells ministers to intervene on digital currency ‘programming’

June 21, 2021

Tips for checking smoke alarms during daylight saving time

March 12, 2022

GLOBAL MARKETS-U.S. stocks follow Europe up; Treasury yields rise, dollar firm

July 9, 2021

What will Durham County education bonds pay for? A full list

July 8, 2022
African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

African currencies week ahead: Zambia's kwacha seen on back foot, Kenyan shilling up – Business Recorder

0
Maxum Foods releases Global Dairy Commodity Update for June

Maxum Foods releases Global Dairy Commodity Update for June

0
Letter: Perpetual bonds can help states fight hunger

Letter: Perpetual bonds can help states fight hunger

0
United Kingdom ETFs Are Riding the Re-Opening Momentum

United Kingdom ETFs Are Riding the Re-Opening Momentum

0

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Industrial Lubricants Market to Reach $71 Billion by 2027.

August 10, 2022

Recent News

Investment in overseas real estate surges : The DONG-A ILBO

August 11, 2022

U.S. inflation CPI report, Wall Street, currencies

August 10, 2022

Alberta oil production set new record in first half of 2022

August 10, 2022

Categories

  • Asia
  • Bonds
  • Canada
  • Commodities
  • Cryptocurrencies
  • Currencies
  • Emerging Markets
  • ETFs
  • Europe & Middle East
  • IPOs
  • Latin America
  • Mutual Funds
  • Personal Finance
  • Real Estate
  • Retirement
  • Spending & Saving
  • Stocks
  • U.S. Markets
  • Privacy & Policy
  • About Us
  • Contact Us
  • Advertise with us

© 2021 Copyright Market-Reporter

No Result
View All Result
  • Home
  • Markets
    • U.S. Markets
    • Canada
    • Europe & Middle East
    • Emerging Markets
    • Asia
    • Latin America
  • Investing
    • Stocks
    • IPOs
    • Mutual Funds
    • ETFs
    • Bonds
    • Commodities
    • Currencies
    • Cryptocurrencies
  • Economy & Politics
    • Personal Finance
    • Spending & Saving
    • Retirement
    • Real Estate

© 2021 Copyright Market-Reporter